2 transcripts
MDGL
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
hepatologists and gastroenterologists that we are targeting, who are caring for the vast majority of the 315,000 diagnosed F2/F3 patients
MDGL
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
efficiently prescribed. Our field team was trained on the Rezdiffra label post approval, enabling them to start calling on their target physicians. Our teams
- Prev
- 1
- Next